Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

EQA round: AP1/22 - Antithrombotic Agents

Deadline: 01.04.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U_{AV} = expanded uncertainty of the assigned value (k = 2)	

Test [unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}
Set 1														
(108) Apixaban [µg/L]				33								33	33	100%
Samples and groups														
Sample A1	216	14	6,6	33		CVP	216	6,1	25%	162	270	33	33	100%
(38) IL	224	8,6	3,8	10	0							10		
(94) Stago	207	6,7	3,2	7	0							7		
(149) Siemens (Dade, BN, Dimension)	215	2,1	1,0	5	0							5		
(193) HYPHEN BioMed	213	22	11	8	0							8		
Other				3	0	3x 179						3		
Sample B1	417	24	5,8	33		CVP	417	10	25%	312	522	33	33	100%
(38) IL	434	14	3,2	10	0							10		
(94) Stago	412	16	4,0	7	0							7		
(149) Siemens (Dade, BN, Dimension)	407	7,4	1,8	5	0							5		
(193) HYPHEN BioMed	417	44	11	8	0							8		
Other				3	0	3x 179						3		
Set 2														
(109) Dabigatran [µg/L]				34								34	31	91%
Samples and groups														
Sample A2	283	45	16	34		CVP	283	19	34%	186	380	34	31	91%
(38) IL	287	47	16	10	0							10		
(149) Siemens (Dade, BN, Dimension)	250	22	8,7	8	0							8		
(193) HYPHEN BioMed	315	33	10	12	1							12		
Other				4	0	1x 94, 3x 179						4		
Sample B2	98,1	17	18	34		CVP	98,1	7,2	34%	64,7	132	34	33	97%
(38) IL	100	12	12	10	0							10		
(149) Siemens (Dade, BN, Dimension)	82,0	7,4	9,0	8	0							8		
(193) HYPHEN BioMed	112	9,8	8,8	12	0							12		
Other				4	0	1x 94, 3x 179						4		
Set 3														
(110) Rivaroxaban [µg/L]				40								40	40	100%
Samples and groups														
Sample A3	305	26	8,5	40		CVP	305	10	25%	228	382	40	40	100%
(38) IL	285	7,4	2,6	12	0							12		
(94) Stago	304	11	3,7	7	0							7		
(149) Siemens (Dade, BN, Dimension)	313	43	14	5	0							5		
(193) HYPHEN BioMed	323	18	5,7	11	0							11		
Other				5	0	1x 162, 4x 179						5		
Sample B3	92,8	7,3	7,9	40		CVP	92,8	2,8	25%	69,6	116	40	40	100%
(38) IL	93,4	5,8	6,2	12	0							12		
(94) Stago	87,5	6,7	7,6	7	0							7		
(149) Siemens (Dade, BN, Dimension)	94,2	3,3	3,5	5	0							5		
(193) HYPHEN BioMed	96,1	11	11	11	0							11		
Other				5	0	1x 162, 4x 179						5		